Analysts See $-0.21 EPS for Translate Bio, Inc. (TBIO)

Analysts expect Translate Bio, Inc. (NASDAQ:TBIO) to report $-0.21 EPS on February, 14.After having $-0.97 EPS previously, Translate Bio, Inc.’s analysts see -78.35 % EPS growth. The stock decreased 0.33% or $0.02 during the last trading session, reaching $6.13. About 41,255 shares traded. Translate Bio, Inc. (NASDAQ:TBIO) has 0.00% since January 12, 2018 and is . It has by 0.00% the S&P500.

Translate Bio, Inc. (NASDAQ:TBIO) Ratings Coverage

Among 3 analysts covering Translate Bio (NASDAQ:TBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Translate Bio had 4 analyst reports since July 23, 2018 according to SRatingsIntel. The company was maintained on Wednesday, November 14 by Leerink Swann.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. The company has market cap of $276.72 million. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It currently has negative earnings. It has strategic alliances with Sanofi Pasteur.

More notable recent Translate Bio, Inc. (NASDAQ:TBIO) news were published by: which released: “Translate Bio Could Be The Next Big Thing In Cystic Fibrosis – Seeking Alpha” on June 08, 2018, also with their article: “Term Sheet — Thursday, June 28 – Fortune” published on June 28, 2018, published: “Translate Bio readies IPO – Seeking Alpha” on June 02, 2018. More interesting news about Translate Bio, Inc. (NASDAQ:TBIO) were released by: and their article: “The 2018 IPO Market’s Most Active Venture Capital Firms – Seeking Alpha” published on December 22, 2018 as well as‘s news article titled: “The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal – Benzinga” with publication date: August 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.